Close Menu

NEW YORK (GenomeWeb) – A PCR-based panel assay from BioMérieux affiliate BioFire Diagnostics to detect 33 common pathogens causing lower respiratory tract infections has been granted 510(k) clearance by the US Food and Drug Administration.

Additionally, a version of the panel with an extra target has obtained CE mark.

The pneumonia panel test detects 18 bacteria and eight viruses, as well as seven genetic markers of antimicrobial resistance. The Plus version of the panel detects the same 33 targets as well as the MERS-CoV virus.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Jul
15
Sponsored by
LGC SeraCare Life Sciences

Cancer immunotherapy is an exciting new advance for the successful treatment of many forms of metastatic cancer.

Jul
23

This webinar will discuss a study that set to assess the efficacy and safety of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC) patients identified by using plasma sample and cobas EGFR Mutation test v2. This is the first prospective study to use liquid biopsy upfront to evaluate osimertinib efficacy.